United Therapeutics hopes its products will be in vein. Its injectable drug Remodulin treats pulmonary hypertension, which affects the blood vessels between the heart and lungs; it also treats cancer and viral illnesses. The product is marketed directly and through distributors in North America, Europe, and the Asia/Pacific region. Other hypertension treatments include Adcirca, Tyvaso, and Orenitram. The company's development pipeline includes additional treatments for cardiovascular disease, as well as various cancers, respiratory conditions, and infectious diseases. United Therapeutics has divested its cardiac monitoring division.
See detailed business credit reports on other businesses or your own.
See detailed profiles for insights and prospects on this company's top competitors.
Essential information for a successful call
- EMPLOYEES (This Site) 13
- EMPLOYEES (All Sites) 750
- ASSETS (MIL USD) 3,401
- SALES (MIL USD) 1,627.8
- TICKER SYMBOL UTHR
- Incorporated 1996
- MARKET VALUE (MIL USD) 3,919.9
- FISCAL YEAR END DEC
- SALES GROWTH % -5.65%
- EMPLOYEE GROWTH % 7.5%
- NET INCOME GROWTH 40.99%
Get in Touch with 4 Contacts
Martine RothblattChairman of the Board and Chief Executive Officer
JAMES C EDGEMONDChief Financial Officer and Treasurer
PAUL A MAHONExecutive Vice President and General Counsel and Secretary
MICHAEL BENKOWITZPresident and Chief Operating Officer